Pulmatrix Inc PULM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:02 PM EDT
1.01UNCH (UNCH)
Volume
179,784
52 week range
0.82 - 3.04

...

Loading . . .
  • Open0.99
  • Day High1.02
  • Day Low0.99
  • Prev Close1.01
  • 52 Week High3.04
  • 52 Week High Date02/10/21
  • 52 Week Low0.82
  • 52 Week Low Date05/11/21

Key Stats

  • Market Cap56.81M
  • Shares Out56.25M
  • 10 Day Average Volume0.74M
  • Dividend-
  • Dividend Yield-
  • Beta1.37
  • YTD % Change-15.13

KEY STATS

  • Open0.99
  • Day High1.02
  • Day Low0.99
  • Prev Close1.01
  • 52 Week High3.04
  • 52 Week High Date02/10/21
  • 52 Week Low0.82
  • 52 Week Low Date05/11/21
  • Market Cap56.81M
  • Shares Out56.25M
  • 10 Day Average Volume0.74M
  • Dividend-
  • Dividend Yield-
  • Beta1.37
  • YTD % Change-15.13

RATIOS/PROFITABILITY

  • EPS (TTM)-0.53
  • P/E (TTM)-1.91
  • Fwd P/E (NTM)-3.74
  • EBITDA (MRQ)-8.995M
  • ROE (MRQ)-58.90%
  • Revenue (MRQ)11.26M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-166.28%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Pulmatrix Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are...
Michael Higgins
Chairman
Teofilo Raad
President
Michelle Siegert
Vice President - Finance
Address
99 Hayden Ave Ste 390
Lexington, MA
02421-7966
United States